<DOC>
	<DOCNO>NCT02850601</DOCNO>
	<brief_summary>The objective single center , 4-week , open label randomize , phase II study evaluate characterize tolerability clinical effectiveness dexamethasone 0.5mg/5ml solution mucoadhesive vehicle ( Mucolox™ ) treatment oral lichen planus .</brief_summary>
	<brief_title>Dexamethasone Solution Treatment Oral Lichen Planus</brief_title>
	<detailed_description>Potentially eligible subject screen one investigator ask patient rate bad oral pain pain score ( 0-10 ) previous week ( see Appendix ) . Those answer least score `` 7 '' ( 1/10 ) meet eligibility requirement ( see Section 3 ) eligible enrollment . All patient sign inform consent study participation . Each study visit anticipate take approximately 45 minute . Treatment administer outpatient basis . Study medication prescribe authorized study staff physicians expense patient . Subjects evaluate clinically baseline start treatment end four-week period , total two visit . Comprehensive subjective objective data collect intraoral photograph obtain . Oral mucosal disease evaluate use patient report ( questions/visual analog scale ) clinician assessed measure . Subjects prescribe compound dexamethasone 0.5mg/5ml solution Mucolox™ ( ARM A ) dexamethasone 0.5mg/5ml solution ( ARM B ) . All subject also receive prescription fluconazole 200 mg tablet once-a-week prophylactic antifungal therapy . Any subject already take antifungal oral medication time study enrollment continue prescribe medication need take additional weekly fluconazole dose . Subjects return evaluation four week time study end-points assess . If worsening oral lichen planus require initiation new immunomodulatory medication ( systemic topical ) , patient remain treatment , regard unevaluable primary endpoint .</detailed_description>
	<mesh_term>Lichen Planus , Oral</mesh_term>
	<mesh_term>Lichen Planus</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age 18 year old . Patients symptomatic oral lichen planus ( bad VAS sensitivity score ≥ 7 last week ) . Patients already topical systemic steroid . Inability comply study instruction . Uncontrolled intercurrent illness psychiatric illness/social situation would limit compliance study requirement . VAS sensitivity score &lt; 7 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Oral lichen planus</keyword>
	<keyword>Dexamethasone solution</keyword>
</DOC>